Home Health Pulmonary Arterial Hypertension Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Acceleron Pharma Inc., United Therapeutics, Altavant Sciences

Pulmonary Arterial Hypertension Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Acceleron Pharma Inc., United Therapeutics, Altavant Sciences

by News Desk
0 comment

The pulmonary arterial hypertension market is expected to surge due to the increasing prevalence and awareness of this disease during the forecast period. Moreover, the launch of various multi-stage pulmonary arterial hypertension pipeline products will revolutionize the dynamics of the pulmonary arterial hypertension market.

of DelveInsight “Pulmonary Arterial Hypertension Market Insights, Epidemiology and Market Forecast-2032” The report provides an in-depth understanding of pulmonary arterial hypertension, historical and projected epidemiology, and trends in the US, EU5 (Germany, Spain, Italy, France, and UK) and Japan pulmonary arterial hypertension markets.

The Pulmonary Arterial Hypertension Market report covers new drugs, current treatment practices, market shares for individual therapies, and current and projected market size from 2019 to 2032. It also assesses current treatment practices/algorithms, market drivers and barriers, and unmet medical opportunities, curates the best opportunities, and assesses market potential.

Click here to know more about Pulmonary Arterial Hypertension market outlook, drug intake, treatment scenarios and epidemiological trends. Pulmonary Arterial Hypertension Market Insights

Overview of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature, primarily affecting the small pulmonary arterioles. PH is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization. The term PAH describes a subset of patients who also have the presence of precapillary hypertension, including end-expiratory pulmonary artery wedge pressure (<15 mmHg) and pulmonary vascular resistance >3 Woods units. There are three subgroups of PAH: idiopathic, hereditary, and pulmonary arterial hypertension associated with risk factors or related conditions.

Some of the Key Facts of the Pulmonary Arterial Hypertension Market Report:

  • The market size of pulmonary arterial hypertension is US$4.901 billion In 2021, it is expected to grow at a significant CAGR during the study period (2019-2032)
  • Total prevalence in the United States was calculated as follows: 53,219 cases alone 31,931 Confirmed Diagnosis in 2019
  • In 2021, The total prevalence of pulmonary arterial hypertension (PAH) is 69,605 cases With 7MM increasing by 2032
  • The female patient pool is approximately 80% of all cases diagnosed in the United States
  • Leading pulmonary artery hypertension companies: Acceleron Pharma Inc., United Therapeutics, Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, etc.
  • Common pulmonary arterial hypertension treatments: sotatercept, lalinepag, rhodatristat Ethy, AV-101, RT234, etc.
  • A gender-based epidemiology of pulmonary arterial hypertension (PAH) analyzes that the prevalence of pulmonary arterial hypertension (PAH) is higher in women than in men.

Get Free Sample of Pulmonary Arterial Hypertension Market Report

https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market

Key Benefits of the Pulmonary Arterial Hypertension Market Report:

  1. The Pulmonary Arterial Hypertension Market Report covers a descriptive overview and comprehensive insights of the Pulmonary Arterial Hypertension Epidemiology and Pulmonary Arterial Hypertension Market for 7MM (US, EU5 (Germany, Spain, France, Italy, UK) and Japan) .
  2. The Pulmonary Arterial Hypertension Market report offers insights on current and emerging therapies.
  3. The Pulmonary Arterial Hypertension Market report provides a global historical and forecast market covering drug outreach of 7 MM.
  4. The Pulmonary Arterial Hypertension Market report provides an edge to help develop business strategies by understanding the trends that will shape and drive the Pulmonary Arterial Hypertension market.

Download the report to understand which factors are driving trends in the epidemiology of pulmonary arterial hypertension @ Epidemiological insights into pulmonary arterial hypertension

pulmonary arterial hypertension market

The dynamics of the pulmonary arterial hypertension market are expected to change in the coming years due to the anticipated launch of novel therapeutics and others during the forecast period of 2019-2032.

“The PAH treatment market looks promising, especially as the market emerges with new therapies recently approved by the FDA to treat PAH. large-scale multicenter trials are still needed.”

Epidemiology of pulmonary arterial hypertension

The epidemiology section provides insights into historical, current and projected epidemiological trends in seven major countries (7MM) from 2019 to 2032. By examining dozens of studies and the views of key opinion leaders, we help you understand the causes of current and projected trends. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epidemiological segmentation of pulmonary arterial hypertension:

The Pulmonary Arterial Hypertension Market report offers an epidemiological analysis for the study period 2019-2032 at 7MM.

  • Total prevalence of pulmonary arterial hypertension
  • Prevalence of pulmonary arterial hypertension by severity
  • Gender prevalence of pulmonary arterial hypertension
  • Diagnosis of episodic and chronic pulmonary arterial hypertension

Uptake and pipeline development activities for drugs for pulmonary arterial hypertension

The Drug Uptake section focuses on the uptake rate of potential drugs that have recently been launched in the Pulmonary Arterial Hypertension market or are expected to be launched during the study period. The analysis covers pulmonary arterial hypertension market uptake by drug, patient uptake by treatment, and sales for each drug.

In addition, the Therapeutic Assessment section helps you understand which drugs are most rapidly absorbed and the reasons behind maximal drug use. Additionally, it compares drugs based on market share.

The report also covers the developmental activities of the Pulmonary Arterial Hypertension pipeline. It provides valuable insight into various therapeutic candidates at various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensed patent details and other information on emerging therapeutics.

Find out more about Therapies Set to Gain Market Share in Leading Pulmonary Arterial Hypertension @ Pulmonary Arterial Hypertension Market Forecast

Pulmonary Arterial Hypertension Drugs and Major Companies

  • Sotatercept: Axelon Pharma K.K.
  • Lalinepag: United Therapeutics
  • Rhodatristat Ethy: Altavant Science
  • AV-101: Aerovate Therapeutics
  • RT234: Respira Therapeutics

Scope of the Pulmonary Arterial Hypertension Market Report

  • Research period: 2019-2032
  • coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Leading pulmonary artery hypertension companies: Acceleron Pharma Inc., United Therapeutics, Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, etc.
  • Common pulmonary arterial hypertension treatments: sotatercept, lalinepag, rhodatristat Ethy, AV-101, RT234, etc.
  • Therapeutic evaluation of pulmonary arterial hypertension: Pulmonary arterial hypertension and emerging drugs currently on the market for pulmonary arterial hypertension
  • Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension Market Drivers and Pulmonary Arterial Hypertension Market Barriers
  • Competitor information analysis: SWOT Analysis, PESTLE Analysis, Porter’s Five Forces, BCG Matrix, Market Entry Strategy
  • Pulmonary Arterial Hypertension Unmet Needs, KOL Opinions, Analyst Opinions, Pulmonary Arterial Hypertension Market Access and Reimbursement

table of contents

1. Introduction of Pulmonary Arterial Hypertension Market Report

2. Summary of Pulmonary Arterial Hypertension

3. SWOT analysis of pulmonary arterial hypertension

4. Patient Share (%) of Pulmonary Arterial Hypertension Overview

5. Pulmonary Arterial Hypertension Market Overview

6. Background and Overview of Pulmonary Arterial Hypertension

7. Epidemiology and prevalence of pulmonary arterial hypertension

8. Number of patients with pulmonary arterial hypertension by country

9. Current Treatment and Practice of Pulmonary Arterial Hypertension

10. Unmet Needs in Pulmonary Arterial Hypertension

11. A new treatment for pulmonary arterial hypertension

12. Pulmonary Arterial Hypertension Market Outlook

13. Pulmonary Arterial Hypertension Market Analysis by Country (2019–2032)

14. Pulmonary Arterial Hypertension Market Access and Treatment Reimbursement

15. Pulmonary Arterial Hypertension Market Drivers

16. Pulmonary Arterial Hypertension Market Barriers

17. Pulmonary Arterial Hypertension Appendix

18. Methodology of pulmonary arterial hypertension report

19. DelveInsight Features

20. Disclaimer

21. About DelveInsight

Learn more about pulmonary arterial hypertension treatment @. Drugs for pulmonary arterial hypertension

media contact
company name: DelveInsight Business Research LLP
contact person: Gaurav Bora
Email: I send a mail
phone: 9193216187
address:304 S. Jones Blvd #2432
City: Las Vegas
state: Nevada
Country: America
Website: https://www.delveinsight.com/

You may also like

Leave a Comment

Copyright ©️ All rights reserved. | Canadian Trends